铁氨酸激酶抑制剂诱导的甲状腺功能低下症:机制和临床影响
Zhipeng Wang1, Hongsen Wang1,2, Chen Bu1
1Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China.
European journal of clinical pharmacology
|March 14, 2024
概括
氨酸激酶抑制剂 (TKIs) 改善癌症存活率,但可能导致甲状腺功能低下. 本综述探讨了TKI诱导的甲状腺功能低下症的流行病学,机制和临床影响,这是癌症治疗中的一个重大问题.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKI) 是有效的抗癌药物,可以改善患者的生存率.
- TKIs针对各种类型的氨酸激酶,抑制癌细胞信号通路.
- 副作用,特别是甲状腺功能障碍,是TKI治疗的新兴问题.
研究的目的:
- 审查使用TKI治疗的癌症患者甲状腺功能低下的流行病学.
- 阐明TKI诱导的甲状腺功能障碍背后的潜在机制.
- 讨论这种不良影响的临床意义和影响.
主要方法:
- 对TKI治疗和甲状腺功能研究的文献综述.
- 对甲状腺功能低下症发病率的流行病学数据的分析.
- 对TKI诱导的甲状腺功能障碍提出的机制的综合.
主要成果:
- 甲状腺功能低下症是接受TKI治疗的患者常见的不良事件.
- 将TKI与甲状腺功能障碍联系在一起的确切机制在很大程度上仍然不清楚.
- 甲状腺功能障碍与TKI治疗疗效有关.
结论:
- 甲状腺功能低下症是TKI癌症治疗的临床相关并发症.
- 需要进一步的研究来充分理解和管理TKI诱导的甲状腺功能障碍.
- 对接受TKI治疗的患者来说,监测甲状腺功能至关重要.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
Functions of Thyroid Hormones
2.7K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
2.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
Receptor Tyrosine Kinases
12.9K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


